Molecular Biology of Bladder Cancer: Potential Implications for Therapy
1Johns Hopkins Greenberg Bladder Cancer Institute, 600 North Wolfe Street, Park 219, Baltimore, MD 21287, USA.
Abstract:
Recently completed studies provided high-resolution descriptions of the molecular biological characteristics of urothelial bladder cancers. Whole transcriptome messenger RNA expression profiling revealed that they can be grouped into basal and luminal molecular subtypes resembling the ones described in breast cancers. Retrospective DNA sequencing efforts revealed roles for disruption of DNA damage response pathways in response to conventional chemotherapy and immune checkpoint blockade, and completed and ongoing studies indicate that the molecular biological properties of infiltrating host cells dictate also influence therapeutic outcomes. This article reviews these findings and identify gaps in knowledge that represent opportunities for future research.
Insights
Urothelial bladder cancers exhibit basal and luminal molecular subtypes. Understanding DNA damage response pathways and host cell properties is crucial for improving chemotherapy and immunotherapy outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Recent studies have elucidated the molecular characteristics of urothelial bladder cancers.
- These cancers can be classified into basal and luminal subtypes based on gene expression, similar to breast cancer subtypes.
Purpose of the Study:
- To review recent findings on the molecular subtypes of urothelial bladder cancer.
- To identify knowledge gaps and future research opportunities in bladder cancer biology and treatment.
Main Methods:
- Whole transcriptome messenger RNA expression profiling to identify molecular subtypes.
- Retrospective DNA sequencing to investigate genetic alterations in DNA damage response pathways.
Main Results:
- Urothelial bladder cancers are categorized into basal and luminal molecular subtypes.
- Disruptions in DNA damage response pathways are implicated in treatment response.
- The molecular profile of infiltrating host cells impacts therapeutic outcomes.
Conclusions:
- Molecular subtyping provides a framework for understanding bladder cancer heterogeneity.
- Targeting DNA damage response pathways and host immune cells holds therapeutic potential.
- Further research is needed to translate these molecular insights into clinical practice.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...